HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

• Published in: Breast cancer research and treatment Vol. 178; no. 2; pp. 275 - 281
• Main Authors: Liu, Yuanyuan, Wu, Shafei, Shi, Xiaohua, Luo, Yufeng, Pang, Junyi, Wang, Changjun, Mao, Feng, Liang, Zhiyong, Zeng, Xuan
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.11.2019; Springer; Springer Nature B.V
• Subjects: Analysis; Asian Continental Ancestry Group; Breast cancer; Breast Neoplasms - epidemiology; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer; Cancer patients; Cancer research; Care and treatment; China - epidemiology; Epidermal growth factor; ErbB-2 protein; Female; Fluorescence in situ hybridization; Gene Amplification; Gene Expression; Health aspects; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Invasiveness; Medical colleges; Medical societies; Medicine; Medicine & Public Health; Neoplasms; Oncology; Patient compliance; Patients; Pertuzumab; Preclinical Study; Prognosis; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; China; FISH; Breast cancer; Equivocal; HER2; IHC
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-019-05387-6

Purpose Human epidermal growth factor receptor 2 (HER2) status is both an independent prognostic factor and a predictive factor for the efficacy of targeted therapy for breast cancer, so it is critical to accurately detect HER2 protein expression and/or gene amplification. According to the recommendations of the 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines for HER2 breast cancer testing, an additional test should be pursued on a different block from the same tumor as one of the options for patients with immunohistochemistry (IHC) 2+ and a HER2/CEP17 ratio of < 2.0 with an average HER2 signals per tumor cell of ≥ 4.0 and < 6.0 by reflex test using dual-probe fluorescence in situ hybridization (FISH) (double-equivocal HER2). Our aim in this study is to explore the consistency of HER2 status between the two blocks. Methods We retrospectively analyzed 5685 primary invasive breast cancers between April 2015 and January 2019 from Peking Union Medical College Hospital. For cases with double-equivocal HER2 revealed in initial blocks, HER2 gene status was evaluated by FISH in a different block from the same tumor. The FISH score was interpreted according to the 2013 ASCO/CAP guidelines for HER2 testing. Results In our cohort of 5685 specimens, the overall HER2 IHC3+, 2+, 1+ and 0 cases were 20.5%, 31.8%, 28.3%, and 19.5%, respectively. Then, 13.7%, 66.3%, and 20.0% of HER2 amplification, non-amplification, and equivocation rates were found, respectively, in IHC2+ patients ( n  = 1777) by reflex FISH assay. For specimens with double-equivocal HER2 ( n  = 333), HER2 status was assessed in another block from the same tumor by FISH and then the frequency of HER2 positive, negative, and equivocation was estimated at 5.7%, 22.5%, and 71.8%, respectively. Because double-equivocal HER2 cases are classified in the HER2 negative category by the 2018 ASCO/CAP HER2 testing guidelines, only 1.3% (19/1511) of HER2 positive patients were determined through additional HER2 testing in another block from the HER2 negative population. Conclusions HER2 status in different blocks from the same tumor in primary invasive breast cancer was highly concordant. Our data supported the recommendation of the 2018 ASCO/CAP HER2 testing guidelines in breast cancer to remove the suggestion for additional HER2 testing using another block contained in the previous version.